Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Re; Drop in SP

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Feb 11, 2021 10:25am

89 Views

Post# 32537110

RE:RE:Re; Drop in SP

Yes I view it as a healthy sign of a litlte profit taking and the broader market is down today as well. Been buying a small amount of shares at the end yesterday and this morning in anticipation of the next set of news.

Like you said Mugs, it takes a bit of time for people to get through reading the company info. So far I've got 3 new people taking positions in ATE this week and I know 2 more buying tomorrow; hope that is indicative of the broader retail market!

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – July 3, 2024